New immunotherapy combo shows promise for advanced lung cancer in early trial
NCT ID NCT03233139
First seen Feb 14, 2026 · Last updated May 25, 2026 · Updated 15 times
Summary
This early-phase study tests the safety and effectiveness of cemiplimab, an immunotherapy drug, alone or combined with other agents in Japanese patients with advanced lung cancer. The goal is to see if these treatments can shrink tumors by helping the immune system attack cancer cells. About 146 participants will be enrolled, and the study focuses on side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gunma Prefectural Cancer Center
Ōta, Gunma, 373-8550, Japan
-
Hiroshima City Hiroshima Citiz
Hiroshima, 730-8518, Japan
-
Kanagawa Cancer Center - Thora
Yokohama, Kanagawa, 241-8515, Japan
-
Kanagawa Cardiovascular and Respiratory Center
Yokohama, Kanagawa, 236-0051, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kansai Medical University Hirakata Hospital
Hirakata, Osaka, 573-1191, Japan
-
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0375, Japan
-
Kobe City Medical Center General Hospital
Kobe, Hyōgo, 650-0047, Japan
-
Kurashiki Central Hospital
Kurashiki, Okayama-ken, 710-8602, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Nagasaki University Hospital
Nagasaki, 852-8501, Japan
-
National Cancer Center Hospital - Tsukiji Campus
Chuo Ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Kinki-chuo Chest Medical Center
Sakai-shi, Osaka, 591-8555, Japan
-
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
-
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, 569-8686, Japan
-
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586, Japan
-
Saitama Cancer Center
Shinden, Saitama, 362-0806, Japan
-
Sasebo City General Hospital
Sasebo, Nagasaki, 857-8511, Japan
-
Tokushima University Hospital
Tokushima, 770-8503, Japan
Conditions
Explore the condition pages connected to this study.